A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study

References

• LopezAD, ShibuyaK, RaoC, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412.16452599
   PubMed Web of Science ®Google Scholar
• BuistAS, McBurnieMA, VollmerWM, et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750. doi:10.1016/S0140-6736(07)61377-417765523
   PubMed Web of Science ®Google Scholar
• MathersCD, LoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Country Profiles. Greece. Available from: http://www.healthdata.org/greece. Accessed 621, 2019.
   Google Scholar
• ContoliM, SolidoroP, Di MarcoF, et al. Effects of aclidinium on determinants of COPD severity: symptoms and quality of life. Int J Chron Obstruct Pulmon Dis. 2016;11:3043–3050. doi:10.2147/COPD27980401
   PubMed Web of Science ®Google Scholar
• KesslerR, PartridgeMR, MiravitllesM, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–272. doi:10.1183/09031936.0005111021115606
   PubMed Web of Science ®Google Scholar
• MiravitllesM, WorthH, Soler CataluñaJJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122. doi:10.1186/s12931-014-0122-125331383
   PubMed Web of Science ®Google Scholar
• DingB, SmallM, BergströmG, HolmgrenU. A cross-sectional survey of night-time symptoms and impact of sleep disturbance on symptoms and health status in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:589–599. doi:10.2147/COPD28243077
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2019 Available from: http://www.goldcopd.org. Accessed 621, 2019.
   Google Scholar
• BlasiF, CanonicaGW, MiravitllesM. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? Respir Res. 2017;18:19. doi:10.1186/s12931-017-0506-028100244
   PubMed Web of Science ®Google Scholar
• BlasiF, CanonicaGW, CentanniS, et al. Genuair® usability test: results of a national public survey of the elderly. COPD. 2016;13:367–371. doi:10.3109/15412555.2015.106767526645660
   PubMedGoogle Scholar
• MagnussenH, FyrnysB, GreguletzR. Genuair®/Pressair® Inhaler in COPD: The Patient Perspective. COPD. 2019;16:196-205.
   Google Scholar
• WedzichaJA, AgustiA, DonaldsonG, ChuecosF, LamarcaR, Garcia GilE. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: a pooled analysis of five Phase III, randomized, placebo-controlled studies. COPD. 2016;13:669–676. doi:10.3109/15412555.2016.117011127159613
   PubMedGoogle Scholar
• D’UrzoAD, RennardSI, KerwinEM, MergelV, LeselbaumAR, CaractaCF. AUGMENT COPD study investigators. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123. doi:10.1186/s12931-014-0123-025756831
   PubMed Web of Science ®Google Scholar
• JonesPW, SinghD, BatemanED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40:830–836. doi:10.1183/09031936.0022551122441743
   PubMed Web of Science ®Google Scholar
• KerwinEM, D’urzoAD, GelbAF, LakkisH, Garcia GilE, CaractaCF. ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90–101. doi:10.3109/15412555.2012.66149222320148
   PubMedGoogle Scholar
• RennardSI, ScanlonPD, FergusonGT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013;33:893–904. doi:10.1007/s40261-013-0138-1
   PubMed Web of Science ®Google Scholar
• BeierJ, KirstenAM, MrózR, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10:511–522. doi:10.3109/15412555.2013.81462623819698
   PubMedGoogle Scholar
• OlschewskiH, VovesR, WallnerE, ScheidlS, KovacsG, TrinkerM. Wirksamkeit, Sicherheit und Benutzerfreundlichkeit der Trockenpulver-Inhalation von Aclidiniumbromid bei COPD. Atemwegs Lungenkr. 2018;44(1):39–50. doi:10.5414/ATX02273
   Google Scholar
• MarthK, SchullerE, PohlW. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109:616–624. doi:10.1016/j.rmed.2015.02.00425796962
   PubMed Web of Science ®Google Scholar
• LangeP, GodtfredsenNS, OlejnickaB, et al. Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting. Eur Clin Respir J. 2016;3:31232. doi:10.3402/ecrj.v3.3123227387608
   PubMed Web of Science ®Google Scholar
• Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25:2–10. doi:10.1002/pds.389126537534
   PubMed Web of Science ®Google Scholar
• LikertR. A technique for the measurement of attitudes. Arch Psychol. 1932;22:55.
   Google Scholar
• KonSSC, CanavanJL, JonesSE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2:195–203. doi:10.1016/S2213-2600(14)70001-324621681
   PubMed Web of Science ®Google Scholar
• BozdoganH. Model selection and Akaike’s information criterion (AIC): the general theory and its analytical extensions. Psychometrika. 1987;52:345–370. doi:10.1007/BF2294361
   Web of Science ®Google Scholar
• McGarveyL, MoriceAH, SmithJA, et al. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Respir Res. 2016;3:e000148. doi:10.1136/bmjresp-2016-000148
   PubMed Web of Science ®Google Scholar
• TsiligianniI, MettingE, van der MolenT, ChavannesN, KocksJ. Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim Care Respir Med. 2016;26:16040. doi:10.1038/npjpcrm.2016.4027442618
   PubMed Web of Science ®Google Scholar
• LuM, WangX, CaiB, et al. Perception of circadian variation of symptoms in Chinese patients with chronic obstructive pulmonary disease. J Thorac Dis. 2017;9:3888–3895. doi:10.21037/jtd29268398
   PubMed Web of Science ®Google Scholar
• KourlabaG, HillasG, VassilakopoulosT, ManiadakisN. The disease burden of chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2016;11:2179–2189. doi:10.2147/COPD27672323
   PubMed Web of Science ®Google Scholar
• MuñozA, SmallM, WoodR, RiberaA, NuevoJ. The impacts of morning, daytime, and nighttime symptoms on disease burden in real-world patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1557–1568. doi:10.2147/COPD29805254
   PubMed Web of Science ®Google Scholar
• StephensonJJ, CaiQ, MocarskiM, TanH, DoshiJA, SullivanSD. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577–586. doi:10.2147/COPD25844033
   PubMed Web of Science ®Google Scholar
• MiravitllesM, RiberaA. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18:67. doi:10.1186/s12931-017-0548-328431503
   PubMed Web of Science ®Google Scholar
• ChapmanKR, BeckE, AlcaideD, Garcia GilE. Overall and cardiovascular safety of aclidinium bromide in patients with COPD: a pooled analysis of six phase III, placebo-controlled, randomized studies. Chronic Obstr Pulm Dis. 2015;3:435–445. doi:10.15326/jcopdf.3.1.2015.014828848864
   PubMed Web of Science ®Google Scholar